|Bid||8.58 x 800|
|Ask||8.59 x 3200|
|Day's Range||8.52 - 8.64|
|52 Week Range||7.73 - 13.30|
|Beta (5Y Monthly)||1.30|
|PE Ratio (TTM)||12.96|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Nov 27, 2017|
|1y Target Est||11.36|
Subscribe to Yahoo Finance Plus to view Fair Value for TEVALearn more
In this piece, we will take a look at the 10 best stocks to buy today according to value investor David Abrams. If you want to take a look only at the top five stocks in this list then head on over to 5 Best Stocks to Buy Today According to Value Investor David Abrams. […]
If we strictly looked at the performance of the major U.S. stock indexes, 2021 was a great year. While no investor enjoys seeing their stocks go in reverse, patience has a way of paying off handsomely in the stock market. In 2022, the following trio of turnaround stocks have the catalysts needed to bounce back in a big way.
(Reuters) -Teva Pharmaceutical Industries Ltd has agreed to pay $420 million to settle shareholder litigation alleging the company hid an anti-competitive scheme to fix the price of generic drugs. Teva spokesperson Kelley Dougherty said the "vast majority" of the settlement will be funded by the company's insurers. "This resolution is in the overall best interest of Teva and the patients who continue to rely on us each day for the world’s largest portfolio of generics medicines," Dougherty said in an email.